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D
ear Editor,
We thank Drs. Zaidan and Wang for their interest 
in our study. There may be some confusion over the 
threshold for vitamin D deiciency. We used the threshold 
of 50 nmol/L or 20 ng/mL as recommended in the UK 
(1), the Institute of Medicine in the United States (2), and 
by the Fourth International Workshop on Asymptomatic 
Primary Hyperparathyroidism (3). In our group, we 
found that 3 of 11 patients identiied with normocalcemic 
hyperparathyroidism (NPHPT) had 25(OH)D levels 
above 75 nmol/L on the index date for our study.
Drs. Zaiden and Wang mentioned that there were 2 
patients with consistently high parathyroid hormone 
(PTH), but actually there were 7 such patients. In the 
remaining 4 patients (S0757, S0911, S3021, S3812), 
3 were receiving vitamin D supplements and 2 of them 
had 25(OH)D >75 nmol/L at the time of diagnosis.
We are aware of the recent study evaluating free 25(OH)
D in patients with NPHPT (4). These are interesting data 
and merit further study. However, free 25(OH)D is not 
part of the routine clinical practice at the moment, in part 
because we do not have an established threshold value.
Among the 4 patients found in our study to have con-
sistent normocalcemia throughout their follow-up, none 
was on calcium supplements at the time of the diagnosis. 
Two reported relatively low calcium intake in their diet 
(less than 500 mg per day). From the remaining patients 
with intermittent hypercalcemia, only 1 was receiving cal-
cium supplements on the index date for our study.
We do believe that these patients have a mild form of pri-
mary hyperparathyroidism. Our understanding is that in the 
case of parathyroid apoplexy, persistently high PTH returns 
to normal (5), which is not a pattern seen in our patients.
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